<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: following risks actually", fill: "#a3c1ad"},
{source: "3: following risks actually", target: "3: operations", fill: "#a3c1ad"},
{source: "3: operations", target: "3: financial condition could suffer", fill: "#a3c1ad"},
{source: "3: financial condition could suffer", target: "3: significantly", fill: "#a3c1ad"},
{source: "3: following risks actually", target: "9: development", fill: "#841b2d"},
{source: "9: development", target: "9: drug delivery technologies along with marketing", fill: "#841b2d"},
{source: "9: drug delivery technologies along with marketing", target: "9: selling expenses", fill: "#841b2d"},
{source: "9: selling expenses", target: "9: administrative expenses", fill: "#841b2d"},
{source: "9: development", target: "11: combination", fill: "#96ded1"},
{source: "11: combination", target: "11: equity financings", fill: "#96ded1"},
{source: "11: equity financings", target: "11: product sales", fill: "#96ded1"},
{source: "11: product sales", target: "11: product development", fill: "#96ded1"},
{source: "11: product development", target: "11: license revenues will", fill: "#96ded1"},
{source: "11: license revenues will", target: "11: provide us with sufficient funds", fill: "#96ded1"},
{source: "11: combination", target: "15: These ", fill: "#df00ff"},
{source: "15: These ", target: "15: technologies from current", fill: "#df00ff"},
{source: "15: technologies from current", target: "15: future biotechnology", fill: "#df00ff"},
{source: "15: future biotechnology", target: "15: pharmaceutical partners", fill: "#df00ff"},
{source: "15: pharmaceutical partners", target: "15: manufacture products efficiently", fill: "#df00ff"},
{source: "15: manufacture products efficiently", target: "15: outsource manufacturing", fill: "#df00ff"},
{source: "15: outsource manufacturing", target: "15: capacity", fill: "#df00ff"},
{source: "15: capacity", target: "15: new product introductions", fill: "#df00ff"},
{source: "15: new product introductions", target: "15: product competition", fill: "#df00ff"},
{source: "15: product competition", target: "15: price competition", fill: "#df00ff"},
{source: "15: price competition", target: "15: patent positions", fill: "#df00ff"},
{source: "15: patent positions", target: "15: additional commercial applications", fill: "#df00ff"},
{source: "15: additional commercial applications", target: "15: regulatory", fill: "#df00ff"},
{source: "15: regulatory", target: "15: commercialization", fill: "#df00ff"},
{source: "15: commercialization", target: "15: reliance on outside consultants", fill: "#df00ff"},
{source: "15: reliance on outside consultants", target: "15: regulatory approvals", fill: "#df00ff"},
{source: "15: regulatory approvals", target: "15: control costs", fill: "#df00ff"},
{source: "15: control costs", target: "15: general economic conditions", fill: "#df00ff"},
{source: "15: These ", target: "18: technologies", fill: "#3c341f"},
{source: "18: technologies", target: "18: combined with", fill: "#3c341f"},
{source: "18: combined with", target: "18: drug which may", fill: "#3c341f"},
{source: "18: drug which may", target: "18: accepted by", fill: "#3c341f"},
{source: "18: accepted by", target: "18: marketplace as", fill: "#3c341f"},
{source: "18: technologies", target: "35: manufacturers", fill: "#d2691e"},
{source: "35: manufacturers", target: "35: manufacturing", fill: "#d2691e"},
{source: "35: manufacturing", target: "35: candidates", fill: "#d2691e"},
{source: "35: manufacturers", target: "155: might also", fill: "#ab4e52"},
{source: "155: might also", target: "155: dilutive issuances", fill: "#ab4e52"},
{source: "155: dilutive issuances", target: "155: equity securities", fill: "#ab4e52"},
{source: "155: equity securities", target: "155: cash available", fill: "#ab4e52"},
{source: "155: cash available", target: "155: operations", fill: "#ab4e52"},
{source: "155: operations", target: "155: connection", fill: "#ab4e52"},
{source: "155: connection", target: "155: with future", fill: "#ab4e52"},
{source: "155: with future", target: "155: acquisitions", fill: "#ab4e52"},
{source: "155: might also", target: "164: developments could", fill: "#9b870c"},
{source: "164: developments could", target: "164: trading price", fill: "#9b870c"},
{source: "164: trading price", target: "164: common stock", fill: "#9b870c"},
{source: "164: developments could", target: "START_HERE", fill: "#9b870c"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Drug Retail</td>
    </tr>
    <tr>
      <td>Oil and Gas Refining and Marketing and Transportation</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Veto</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Demonstrate</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HCL_Technologies">HCL Technologies</a></td>
      <td>HCL Technologies (Hindustan Computers Limited) is an Indian multinational information technology (IT) services and consulting company headquartered in Noida. It is a subsidiary of HCL Enterprise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Palantir_Technologies">Palantir Technologies</a></td>
      <td>Palantir Technologies is a public American software company that specializes in big data analytics. Headquartered in Denver, Colorado, it was founded by Peter Thiel, Nathan Gettings, Joe Lonsdale, Stephen Cohen, and Alex Karp in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Technologies">United Technologies</a></td>
      <td>United Technologies Corporation (UTC) was an American multinational conglomerate headquartered in Farmington, Connecticut.  It researched, developed, and manufactured products in numerous areas, including aircraft engines, aerospace systems, HVAC, elevators and escalators, fire and security, building automation, and industrial products, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lumen_Technologies">Lumen Technologies</a></td>
      <td>Lumen Technologies, Inc. (formerly CenturyLink) is an American \ntelecommunications company headquartered in Monroe, Louisiana, that offers communications, network services, security, cloud solutions, voice, and managed services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_Consent">Manufacturing Consent</a></td>
      <td>Manufacturing Consent: The Political Economy of the Mass Media is a 1988 book by Edward S. Herman and Noam Chomsky. It argues that the mass communication media of the U.S. "are effective and powerful ideological institutions that carry out a system-supportive propaganda function, by reliance on market forces, internalized assumptions, and self-censorship, and without overt coercion", by means of the propaganda model of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ANTARES PHARMA INC      Item 1A RISK FACTORS        The following “risk factors” contain important information <font color="blue">about us</font> and our     business  and  should  be read in their entirety</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and     <font color="blue">uncertainties</font> not known to us or that we now believe to be not material     could                                            23     ______________________________________________________________________    [24]Index to <font color="blue">Financial Statements       </font><font color="blue">also impair</font> our business</td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">following risks actually</font> occur, our     business,  results  of <font color="blue">operations</font> and <font color="blue"><font color="blue"><font color="blue">financial condition</font> could</font> suffer</font>     <font color="blue"><font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td>As a result, the <font color="blue">market price</font> of our <font color="blue">common stock</font> could     decline and you could lose all of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>In this Section, the     terms “we” and “our” refer to Antares Pharma, Inc</td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related </font>to Our Operations        We have <font color="blue">incurred <font color="blue">significant</font> losses</font> to date, and there is no guarantee that     we <font color="blue">will ever become profitable</font>        We had working capital of dlra965cmam169 at <font color="blue">December </font>31, 2005, and dlra8cmam489cmam253 at     <font color="blue">December </font>31, 2004</td>
    </tr>
    <tr>
      <td>We incurred net losses of (dlra8cmam497cmam956) and (dlra8cmam348cmam532)     in the <font color="blue">fiscal years</font> ended 2005 and 2004, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>In addition, we have     <font color="blue">accumulated aggregate net losses from</font> the inception of business through     <font color="blue">December </font>31, 2005 of (dlra91cmam123cmam107)</td>
    </tr>
    <tr>
      <td>The costs for research and product     <font color="blue">development</font> of our <font color="blue"><font color="blue">drug delivery</font> <font color="blue">technologies</font> <font color="blue">along with</font> marketing</font> and     <font color="blue">selling expenses</font> and general and <font color="blue">administrative expenses</font> have been the     principal causes of our losses</td>
    </tr>
    <tr>
      <td>We completed <font color="blue">private placements</font> in March 2006 and <font color="blue">February and March </font>2004 in     which we received aggregate gross proceeds of dlra10cmam962cmam500 and dlra15cmam120cmam000,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>We believe that the <font color="blue">combination</font> of these <font color="blue">equity financings</font> and     projected <font color="blue">product sales</font> and product <font color="blue">development</font> and <font color="blue">license revenues will</font>     <font color="blue">provide us with sufficient funds</font> to support <font color="blue">operations</font> beyond 2006</td>
    </tr>
    <tr>
      <td>However,     if we need <font color="blue"><font color="blue">additional</font> financing</font> and are unable to obtain <font color="blue">such financing</font> when     needed, or obtain it on favorable terms, we may be required to curtail     <font color="blue">development</font> of new drug <font color="blue">technologies</font>, limit expansion of <font color="blue">operations</font>, accept     <font color="blue">financing terms</font> that are not <font color="blue">as attractive as</font> we may desire or be forced to     liquidate and close <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Long-term capital <font color="blue">requirements</font> will <font color="blue">depend on</font> numerous factors, including,     but not limited to, the status of <font color="blue"><font color="blue">collaborative</font> <font color="blue">arrangements</font></font>, the progress     of research and <font color="blue">development</font> programs and the receipt of <font color="blue"><font color="blue">revenues from</font> sales</font>     of products</td>
    </tr>
    <tr>
      <td>Our ability to achieve and/or sustain profitable <font color="blue">operations</font>     <font color="blue">depends on</font> a number of factors, many of which are beyond our control</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>factors include, but are not limited to, the following:           •   the demand for our <font color="blue"><font color="blue">technologies</font> from current</font> and <font color="blue">future <font color="blue">bio<font color="blue">technology</font></font></font>     and <font color="blue"><font color="blue">pharmaceutical</font> partners</font>;           •   our ability to <font color="blue"><font color="blue">manufacture</font> products efficiently</font> and with the required     quality;           •   our ability to increase and continue to <font color="blue">outsource <font color="blue">manufacturing</font></font>     <font color="blue">capacity</font> to allow for <font color="blue">new product <font color="blue">introduction</font>s</font>;           •   the level of <font color="blue">product <font color="blue">competition</font></font> and of <font color="blue">price <font color="blue">competition</font></font>;           •   our ability to develop, maintain or acquire <font color="blue">patent positions</font>;           •   our ability to develop <font color="blue"><font color="blue">additional</font> <font color="blue">commercial <font color="blue">applications</font></font></font> for our     products;           •   our limited <font color="blue">regulatory</font> and <font color="blue">commercialization</font> experience;           •   our <font color="blue">reliance on outside consultants</font>;           •   our ability to obtain <font color="blue">regulatory</font> approvals;           •   our ability to attract the right personnel to execute our plans;           •   our ability to <font color="blue">control costs</font>; and           •   <font color="blue">general economic conditions</font></td>
    </tr>
    <tr>
      <td>As we changed our business model to be more <font color="blue">commercially oriented by further</font>     developing our own products, we may not have <font color="blue">sufficient resources</font> to fully     execute our plan</td>
    </tr>
    <tr>
      <td>We  must  make  choices  as to the drugs that we <font color="blue">will combine with</font> our     transdermal gel, fast-melt tablet and disposable mini-needle <font color="blue">technologies</font> to     move into the marketplace</td>
    </tr>
    <tr>
      <td>We may not make the correct choice of drug or     <font color="blue">technologies</font> when <font color="blue">combined with</font> a drug, which may not be <font color="blue">accepted by</font> the     <font color="blue">marketplace as</font> we expected or at all</td>
    </tr>
    <tr>
      <td>FDA <font color="blue"><font color="blue">approval process</font>es</font> for the drugs     and <font color="blue">drugs with devices may</font> be longer in time and/or more costly and/or     require more <font color="blue">extended clinical evaluation than</font> anticipated</td>
    </tr>
    <tr>
      <td>Funds required     to bring our own products to <font color="blue">market may</font> be more than anticipated or may not     be <font color="blue">available at</font> all</td>
    </tr>
    <tr>
      <td>We have limited experience in <font color="blue">development</font> of compounds     and in <font color="blue">regulatory</font> matters and <font color="blue">bringing such products</font> to market; therefore,     we may experience <font color="blue"><font color="blue">difficult</font>ies</font> in making this change or not be able to     achieve the change at all</td>
    </tr>
    <tr>
      <td>24     ______________________________________________________________________    [25]Index to <font color="blue">Financial Statements       </font>We <font color="blue">currently <font color="blue">depend on</font></font> a limited number of customers for the majority of our     revenue, and the loss of any one of these <font color="blue">customers could <font color="blue">substantially</font></font>     reduce our revenue and impact our liquidity        During 2005, we derived <font color="blue">approximately</font> 48prca and 12prca of our revenue, from     Ferring and JCR Pharmaceuticals, Co, Ltd, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>The loss of either of these <font color="blue">customers would</font> cause our revenues to decrease     <font color="blue"><font color="blue">significant</font>ly</font>,  increase  our  continuing  losses from <font color="blue">operations</font> and,     ultimately, could require us to cease operating</td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot broaden</font> our     customer  base,  we <font color="blue">will continue</font> to <font color="blue">depend on</font> a <font color="blue">few customers</font> for the     majority  of our revenues</td>
    </tr>
    <tr>
      <td>Additionally, if we are unable to negotiate     favorable business terms with these customers in the future, our revenues     and gross <font color="blue">profits may</font> be insufficient to allow us to achieve and/or sustain     <font color="blue">profitability</font> or continue <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we or our third-party <font color="blue">manufacture</font>r are unable to supply Ferring with our     devices pursuant to our <font color="blue">current license <font color="blue">agreement</font> with</font> Ferring, Ferring     would own a <font color="blue">fully paid up license</font> for certain of our <font color="blue">intellectual</font> property        Pursuant to our license <font color="blue">agreement</font> with Ferring, we <font color="blue">licensed certain</font> of our     <font color="blue">intellectual</font>  property  related  to our needle-free injection devices,     including a license that allows Ferring to <font color="blue">manufacture</font> our devices on its     own for use with its <font color="blue">human growth hormone</font> product</td>
    </tr>
    <tr>
      <td>This <font color="blue">license becomes</font>     <font color="blue">effective</font> if we are unable to continue to <font color="blue">supply product</font> to Ferring under     our current supply <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>In <font color="blue"><font color="blue">accordance</font> with</font> the license <font color="blue">agreement</font>, we     <font color="blue">entered into</font> a <font color="blue">manufacturing</font> <font color="blue">agreement</font> with a <font color="blue">third party</font> to <font color="blue">manufacture</font> our     devices  for Ferring</td>
    </tr>
    <tr>
      <td>If we or this <font color="blue">third party</font> are unable to meet our     <font color="blue">obligations</font> to supply Ferring with our devices, Ferring would own a fully     paid  up license to <font color="blue">manufacture</font> our devices and to use and exploit our     <font color="blue">intellectual</font> property in <font color="blue"><font color="blue">connection</font> with</font> Ferring’s <font color="blue">human growth hormone</font>     product</td>
    </tr>
    <tr>
      <td>In  such  event,  we  would  no  longer receive royalties or     <font color="blue"><font color="blue">manufacturing</font> margins from</font> Ferring</td>
    </tr>
    <tr>
      <td>If we do not develop and maintain <font color="blue">relationships with</font> <font color="blue">manufacture</font>rs of our     drug <font color="blue">candidates</font>, then we may not <font color="blue">successfully</font> <font color="blue">manufacture</font> and sell our     <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td>We do not possess the capabilities, resources or <font color="blue">facilities</font> to <font color="blue">manufacture</font>     Anturol™, which is currently in <font color="blue">clinical studies</font> for <font color="blue">over active bladder</font>, or     any other of our <font color="blue">future drug <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We must <font color="blue">contract with</font> <font color="blue">manufacture</font>rs     to  produce  Anturol™  <font color="blue">according</font> to <font color="blue">government <font color="blue">regulations</font></font></td>
    </tr>
    <tr>
      <td>Our future     <font color="blue">development</font> and delivery of our product <font color="blue">candidates</font> <font color="blue">depends on</font> the timely,     profitable and <font color="blue"><font color="blue">competitive</font> performance</font> of these <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>A limited     number of <font color="blue">manufacture</font>rs exist which are capable of <font color="blue">manufacturing</font> our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We may fail to <font color="blue">contract with</font> the necessary <font color="blue">manufacture</font>rs or we     may <font color="blue">contract with</font> <font color="blue">manufacture</font>s on terms that may not be entirely acceptable     to us</td>
    </tr>
    <tr>
      <td>Our <font color="blue">manufacture</font>rs must obtain FDA approval for their <font color="blue">manufacturing</font>     processes, and we have <font color="blue">no control over</font> this <font color="blue">approval process</font></td>
    </tr>
    <tr>
      <td>We have not <font color="blue">contracted with</font> a <font color="blue">commercial supplier</font> of <font color="blue">active <font color="blue">pharmaceutical</font></font>     <font color="blue">ingredients</font> of oxybutynin for Anturol™</td>
    </tr>
    <tr>
      <td>We are currently working towards     selecting a <font color="blue">manufacture</font>r to <font color="blue">provide us with oxybutynin</font> in a <font color="blue">manner which</font>     meets FDA <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">contracted with</font> Patheon, a <font color="blue">manufacturing</font> <font color="blue">development</font> company, to     supply  clinical  quantities  of  Anturol™  in a manner that meets FDA     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>The FDA has not approved the <font color="blue">manufacturing</font> processes of     Patheon</td>
    </tr>
    <tr>
      <td>Any <font color="blue">failure by</font> Patheon to achieve compliance with FDA standards     could <font color="blue"><font color="blue">significant</font>ly</font> harm our business since we do not have an approved     secondary <font color="blue">manufacture</font>r for Anturol™</td>
    </tr>
    <tr>
      <td>We  have  limited  device  <font color="blue">manufacturing</font> experience and may experience     <font color="blue">manufacturing</font> <font color="blue"><font color="blue">difficult</font>ies</font> related to the use of new device materials and     procedures, <font color="blue">which could</font> increase our <font color="blue">production costs</font> and, ultimately,     decrease our profits        Our past assembly, testing and device <font color="blue">manufacturing</font> experience for certain     of  our device <font color="blue">technologies</font> has involved the assembly of <font color="blue">products from</font>     <font color="blue">machined stainless steel</font> and <font color="blue">composite <font color="blue">components</font></font> in limited quantities</td>
    </tr>
    <tr>
      <td>Our     planned <font color="blue">future <font color="blue">drug delivery</font></font> device <font color="blue">technologies</font> necessitate <font color="blue">significant</font>     changes  and  <font color="blue">additions</font>  to  our <font color="blue">manufacturing</font> and <font color="blue">assembly process</font> to     <font color="blue">accommodate new <font color="blue">components</font></font></td>
    </tr>
    <tr>
      <td>These <font color="blue">systems must</font> be <font color="blue">manufacture</font>d in compliance     with  <font color="blue">regulatory</font>  <font color="blue">requirements</font>,  in  a <font color="blue">timely manner</font> and in sufficient     <font color="blue">quantities while</font> maintaining quality and acceptable <font color="blue">manufacturing</font> costs</td>
    </tr>
    <tr>
      <td>In     the course of these changes and <font color="blue">additions</font> to our <font color="blue">manufacturing</font> and                                           25     ______________________________________________________________________    [26]Index to <font color="blue">Financial Statements       </font>production  methods, we <font color="blue">may encounter</font> <font color="blue"><font color="blue">difficult</font>ies</font>, including problems     involving  yields, quality control and assurance, product re<font color="blue">liability</font>,     <font color="blue">manufacturing</font> costs, existing and <font color="blue">new equipment</font>, component supplies and     shortages of personnel, any of <font color="blue">which could</font> result in <font color="blue"><font color="blue">significant</font> delays</font> in     production</td>
    </tr>
    <tr>
      <td>Additionally, in February 2003, we <font color="blue">entered into</font> a <font color="blue">manufacturing</font>     <font color="blue">agreement</font> under which a <font color="blue">third party</font> assembles our MJ7 devices and certain     related disposable component parts</td>
    </tr>
    <tr>
      <td>There can be no assurance that this     third-party <font color="blue">manufacture</font>r will be able to meet these <font color="blue">regulatory</font> <font color="blue">requirements</font>     or our own <font color="blue">quality control standards</font></td>
    </tr>
    <tr>
      <td>Therefore, there can be no assurance     that we will be able to <font color="blue">successfully</font> produce and <font color="blue">manufacture</font> our products</td>
    </tr>
    <tr>
      <td>Any  failure  to do so <font color="blue">would <font color="blue"><font color="blue">negatively</font> impact</font></font> our business, financial     condition  and  results  of  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We are now in the process of     outsourcing <font color="blue">manufacturing</font> of our AJ mini-needle products to <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">products will</font> be <font color="blue">price sensitive</font> and may be required to be <font color="blue">manufacture</font>d     in large quantities, and we have no assurance that this can be done</td>
    </tr>
    <tr>
      <td>Our  products  have  achieved  only limited <font color="blue"><font color="blue">acceptance</font> by patients</font> and     physicians,  <font color="blue">which continues</font> to <font color="blue">restrict marketing penetration</font> and the     resulting sales of more units        Our business ultimately <font color="blue">depends on</font> patient and <font color="blue">physician <font color="blue">acceptance</font></font> of our     needle-free <font color="blue">injectors</font>, gels, fast-melt tablets and our other <font color="blue">drug delivery</font>     <font color="blue">technologies</font> as an <font color="blue">alternative</font> to more <font color="blue">traditional forms</font> of <font color="blue">drug delivery</font>,     including  <font color="blue">injections</font>  using  a needle, orally ingested drugs and more     <font color="blue">traditional transdermal patch products</font></td>
    </tr>
    <tr>
      <td>To date, our device <font color="blue">technologies</font>     have achieved only limited <font color="blue"><font color="blue">acceptance</font> from such parties</font></td>
    </tr>
    <tr>
      <td>The degree of     <font color="blue">acceptance</font> of our <font color="blue">drug delivery</font> systems <font color="blue">depends on</font> a number of factors</td>
    </tr>
    <tr>
      <td>These factors include, but are not limited to, the following:           • advantages over <font color="blue">alternative</font> <font color="blue">drug delivery</font> systems or similar products     from other companies;           • demonstrated clinical efficacy, safety and <font color="blue">enhanced patient compliance</font>;           • cost-<font color="blue">effective</font>ness;           • convenience and ease of use of <font color="blue">injectors</font> and <font color="blue">transdermal gels</font>; and           • marketing and <font color="blue"><font color="blue">distribution</font> support</font></td>
    </tr>
    <tr>
      <td><font color="blue">Physicians </font>may refuse to <font color="blue">prescribe products <font color="blue">incorporating</font></font> our <font color="blue">drug delivery</font>     <font color="blue">technologies</font>  if  they  believe  that  the active ingredient is better     <font color="blue">administered</font> to a patient using <font color="blue">alternative</font> <font color="blue">drug delivery</font> <font color="blue">technologies</font>, that     the time required to <font color="blue">explain use</font> of the <font color="blue">technologies</font> to the <font color="blue">patient would</font>     not be <font color="blue">offset by advantages</font>, or they believe that the <font color="blue">delivery method will</font>     result in <font color="blue">patient noncompliance</font></td>
    </tr>
    <tr>
      <td>Factors <font color="blue">such as patient perceptions</font> that a     gel is <font color="blue">inconvenient</font> to apply or that devices do not deliver the drug at the     same rate as conventional <font color="blue">drug delivery</font> methods may cause patients to reject     our <font color="blue">drug delivery</font> <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Because only a limited number of products     <font color="blue">incorporating</font> our <font color="blue">drug delivery</font> <font color="blue">technologies</font> are <font color="blue">commercially available</font>, we     <font color="blue"><font color="blue">cannot yet</font> fully assess</font> the level of market <font color="blue">acceptance</font> of our <font color="blue">drug delivery</font>     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>A 2002 National Institute of Health (“NIH”) study and the 2003 findings from     the <font color="blue">Million Women Study </font><font color="blue">first launched</font> in 1997 in the UK questioned the     safety of <font color="blue">hormone replacement therapy</font> for <font color="blue">menopausal women</font>, and our female     <font color="blue">hormone replacement therapy</font> business <font color="blue">may suffer as</font> a result        In July 2002, the NIH halted a long-term study, known as the Women’s Health     Initiative, being conducted on oral female <font color="blue">hormone replacement therapy</font>     (“HRT”) using a <font color="blue">combination</font> of estradiol and progestin because the study     showed an <font color="blue">increased risk</font> of <font color="blue">breast cancer</font>, heart disease and <font color="blue">blood clots</font> in     women taking the <font color="blue">combination</font> therapy</td>
    </tr>
    <tr>
      <td>The arm of the <font color="blue">study using estrogen</font>     alone was stopped in March 2004 after the NIH concluded that the benefits of     estrogen did not outweigh the <font color="blue">stroke risk</font> for women in this trial</td>
    </tr>
    <tr>
      <td>The     <font color="blue">halted study looked at only one</font> brand of <font color="blue">oral combined</font> HRT and of estrogen,     and there is no information <font color="blue">on whether brands with different levels</font> of     <font color="blue">hormones would</font> carry the same risk</td>
    </tr>
    <tr>
      <td><font color="blue">In January </font>2003, the FDA announced that     it would require <font color="blue">new warnings on</font> the labels of HRT products, and it advised     patients  to  consult  with their <font color="blue">physicians about whether</font> to continue     <font color="blue">treatment with continuous combined</font> HRT and to limit the period of use to     that  required  to  manage  post-menopausal  vasomotor  <font color="blue">symptoms only</font></td>
    </tr>
    <tr>
      <td>Subsequently, <font color="blue"><font color="blue">additional</font> analysis from</font> the NIH study has suggested a slight     increase in the risk of <font color="blue">cognitive dysfunction</font> developing in <font color="blue">patients on</font>     long-term combined HRT The Million Women Study, conducted in the UK,     confirmed that current and <font color="blue">recent use</font> of HRT increases a woman’s chance of     developing <font color="blue">breast cancer</font> and that the <font color="blue">risk increased with duration</font> of use</td>
    </tr>
    <tr>
      <td><font color="blue">Other HRT </font>studies have <font color="blue">found potential links between</font> HRT and an increased     risk of dementia and asthma</td>
    </tr>
    <tr>
      <td>These results and <font color="blue">recommendations impacted</font> the     use of HRT, and <font color="blue">product sales</font> have diminished <font color="blue"><font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot yet</font>     assess the impact any of the studies’ results may have on our contracts or     on our partners’ perspective of the market for <font color="blue">transdermal gel products</font>     designed for HRT We also                                           26     ______________________________________________________________________    [27]Index to <font color="blue">Financial Statements       </font><font color="blue">cannot predict whether</font> our <font color="blue">alternative</font> route of <font color="blue">transdermal <font color="blue">administration</font></font>     of HRT <font color="blue">products will</font> carry the <font color="blue">same risk as</font> the <font color="blue">oral products used</font> in the     study</td>
    </tr>
    <tr>
      <td>If <font color="blue">transdermal gels</font> do not achieve greater market <font color="blue">acceptance</font>, we may be     unable to achieve <font color="blue">profitability</font>        <font color="blue">Because  </font>transdermal  gels are a newer, less understood method of drug     delivery, our <font color="blue">potential consumers</font> have little experience with <font color="blue">manufacturing</font>     costs or <font color="blue">pricing parameters</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">assumption</font> of <font color="blue">higher value may</font> not be     <font color="blue">shared by</font> the consumer</td>
    </tr>
    <tr>
      <td>To date, <font color="blue">transdermal gels</font> have <font color="blue">gained successful</font>     <font color="blue">entry into only</font> a limited number of markets</td>
    </tr>
    <tr>
      <td>There can be no assurance that     <font color="blue">transdermal gels</font> will ever gain market <font color="blue">acceptance</font> beyond these markets     sufficient to allow us to achieve and/or sustain profitable <font color="blue">operations</font> in     this <font color="blue">product area</font></td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">third parties</font> to <font color="blue">supply <font color="blue">components</font></font> for our products, and any     failure to retain <font color="blue">relationships with</font> these <font color="blue">third parties</font> could <font color="blue">negatively</font>     impact our ability to <font color="blue">manufacture</font> our products        <font color="blue">Certain  </font>of our <font color="blue">technologies</font> contain a number of customized <font color="blue">components</font>     <font color="blue">manufacture</font>d by various <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">requirements</font> applicable to     medical device <font color="blue">manufacturing</font> can make <font color="blue">substitution</font> of <font color="blue">suppliers costly</font> and     time-consuming</td>
    </tr>
    <tr>
      <td>In the event that we could not obtain <font color="blue">adequate quantities</font> of     these customized <font color="blue">components</font> from our suppliers, there can be no assurance     that we would be able to access <font color="blue">alternative</font> sources of such <font color="blue">components</font>     within a reasonable period of time, on acceptable terms or at all</td>
    </tr>
    <tr>
      <td>The     <font color="blue">un<font color="blue">availability</font></font> of <font color="blue">adequate quantities</font>, the inability to develop <font color="blue">alternative</font>     sources, a reduction or <font color="blue">interruption</font> in supply or a <font color="blue"><font color="blue">significant</font> increase</font> in     the price of <font color="blue">components</font> could have a material adverse effect on our ability     to <font color="blue">manufacture</font> and market our products</td>
    </tr>
    <tr>
      <td>We may be unable to <font color="blue">successfully</font> expand into new areas of <font color="blue">drug delivery</font>     <font color="blue">technology</font>, <font color="blue">which could</font> <font color="blue"><font color="blue">negatively</font> impact</font> our business as a whole        We intend to continue to enhance our current <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Even if enhanced     <font color="blue">technologies</font> appear <font color="blue">promising during various stages</font> of <font color="blue">development</font>, we may     not be able to develop <font color="blue">commercial <font color="blue">applications</font></font> for them because           •   the potential <font color="blue">technologies</font> may fail <font color="blue">clinical studies</font>;           •   we may not find a <font color="blue"><font color="blue">pharmaceutical</font> company</font> to adopt the <font color="blue">technologies</font>;           •   it may be <font color="blue">difficult</font> to apply the <font color="blue">technologies</font> on a <font color="blue">commercial scale</font>;           •   the <font color="blue">technologies</font> may not be economical to market; or           •   we may not receive necessary <font color="blue">regulatory</font> approvals for the potential     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We  have  not  yet completed research and <font color="blue">development</font> work or obtained     <font color="blue">regulatory</font> approval for any <font color="blue">technologies</font> for use with any drugs other than     insulin, <font color="blue">human growth hormone</font> and estradiol</td>
    </tr>
    <tr>
      <td>There can be no assurance that     any newly developed <font color="blue">technologies</font> will ultimately be successful or that     unforeseen <font color="blue"><font color="blue">difficult</font>ies</font> will not occur in research and <font color="blue">development</font>, clinical     testing, <font color="blue">regulatory</font> submissions and approval, product <font color="blue">manufacturing</font> and     <font color="blue">commercial scale</font>-up, marketing, or <font color="blue">product <font color="blue">distribution</font></font> related to any such     improved <font color="blue">technologies</font> or new uses</td>
    </tr>
    <tr>
      <td>Any <font color="blue">such occurrence could materially</font>     delay the <font color="blue">commercialization</font> of such improved <font color="blue">technologies</font> or new uses or     prevent their <font color="blue">market <font color="blue">introduction</font> entirely</font></td>
    </tr>
    <tr>
      <td>As <font color="blue">health insurance companies</font> and other third-party payors <font color="blue">increasingly</font>     challenge the products and services for which they <font color="blue">will provide coverage</font>,     our individual <font color="blue">consumers may</font> not be able to receive <font color="blue">adequate <font color="blue">reimbursement</font></font>     or may be unable to afford to use our products, <font color="blue">which could</font> <font color="blue">substantially</font>     reduce our revenues and <font color="blue"><font color="blue">negatively</font> impact</font> our business as a whole        Our injector device products are <font color="blue">currently sold</font> in the European Community     (“EC”)  and  <font color="blue">in the <font color="blue">United States </font></font>for use with <font color="blue">human growth hormone</font> or     insulin</td>
    </tr>
    <tr>
      <td>In the case of <font color="blue">human growth hormone</font>, our products are provided to     users at no cost by the drug <font color="blue">manufacture</font>r</td>
    </tr>
    <tr>
      <td><font color="blue">In the <font color="blue">United States </font></font>the injector     products are legally marketed and available for use with insulin</td>
    </tr>
    <tr>
      <td>Although it is impossible for us to identify the amount of sales of our     products that our <font color="blue">customers will submit</font> for payment to third-party insurers,     at least some of these sales may be <font color="blue">dependent</font> in part on the <font color="blue">availability</font> of     <font color="blue">adequate <font color="blue">reimbursement</font></font> from these third-party healthcare payors</td>
    </tr>
    <tr>
      <td>Currently,     insurance companies and other third-party                                           27     ______________________________________________________________________    [28]Index to <font color="blue">Financial Statements       </font><font color="blue">payors reimburse</font> the cost of certain <font color="blue">technologies</font> on a case-by-case basis     and  may  refuse  <font color="blue">reimbursement</font>  if they do not perceive benefits to a     <font color="blue">technology</font>’s use in a <font color="blue">particular case</font></td>
    </tr>
    <tr>
      <td>Third-party payors are <font color="blue">increasingly</font>     <font color="blue">challenging</font> the pricing of <font color="blue">medical products</font> and services, and there can be     no  assurance  that  such  third-party  payors  will not in the future     <font color="blue">increasingly</font>  reject claims for coverage of the cost of certain of our     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Insurance and third-party payor practice vary from country to     country, and changes in practices could <font color="blue">negatively</font> affect our business if     the cost burden for our <font color="blue">technologies</font> were shifted more to the patient</td>
    </tr>
    <tr>
      <td>Therefore, there can be no assurance that <font color="blue">adequate levels</font> of <font color="blue">reimbursement</font>     will be available to <font color="blue">enable us</font> to achieve or maintain market <font color="blue">acceptance</font> of     our <font color="blue">technologies</font> or maintain <font color="blue">price levels sufficient</font> to realize profitable     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>There is also a <font color="blue">possibility</font> of increased government control or     <font color="blue">influence over</font> a <font color="blue">broad range</font> of <font color="blue">healthcare <font color="blue">expenditures</font></font> in the future</td>
    </tr>
    <tr>
      <td>Any     such trend could <font color="blue"><font color="blue">negatively</font> impact</font> the market for our <font color="blue">drug delivery</font> products     and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>The loss of any existing licensing <font color="blue">agreement</font>s or the failure to enter into     new licensing <font color="blue">agreement</font>s could <font color="blue">substantially</font> affect our revenue        One of our business pathways requires us to enter into license <font color="blue">agreement</font>s     with <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> companies covering the <font color="blue">development</font>,     <font color="blue">manufacture</font>, use and marketing of <font color="blue">drug delivery</font> <font color="blue">technologies</font> with specific     <font color="blue">drug therapies</font></td>
    </tr>
    <tr>
      <td>Under these <font color="blue">arrangements</font>, the <font color="blue">partner company typically</font>     <font color="blue">assists us</font> in the <font color="blue">development</font> of systems for <font color="blue">such <font color="blue">drug therapies</font></font> and collect     or  sponsor  the <font color="blue">collection</font> of the <font color="blue">appropriate data</font> for submission for     <font color="blue">regulatory</font> approval of the use of the <font color="blue">drug delivery</font> <font color="blue">technology</font> with the     licensed  drug  therapy</td>
    </tr>
    <tr>
      <td>Our  licensees  may  also be responsible for     <font color="blue">distribution</font> and marketing of the <font color="blue">technologies</font> for these <font color="blue">drug therapies</font>     <font color="blue">either worldwide</font> or in <font color="blue">specific territories</font></td>
    </tr>
    <tr>
      <td>We are currently a party to a     number of such <font color="blue">agreement</font>s, all of which are currently in <font color="blue">varying stages</font> of     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">meet future milestones established</font> in our     <font color="blue">agreement</font>s (such milestones <font color="blue">generally</font> being <font color="blue">structured around</font> satisfactory     <font color="blue">completion</font> of <font color="blue">certain phases</font> of clinical <font color="blue">development</font>, <font color="blue">regulatory</font> approvals     and <font color="blue">commercialization</font> of our product) and thus, would not receive the fees     expected from such <font color="blue">arrangements</font> or related <font color="blue">future royalties</font></td>
    </tr>
    <tr>
      <td>Moreover, there     can be no assurance that we will be successful in executing <font color="blue">additional</font>     <font color="blue">collaborative</font> <font color="blue">agreement</font>s or that existing or future <font color="blue">agreement</font>s will result     in <font color="blue">increased sales</font> of our <font color="blue">drug delivery</font> <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>In such event, our     business, results of <font color="blue">operations</font> and <font color="blue"><font color="blue">financial condition</font> could</font> be <font color="blue">adversely</font>     affected, and our revenues and gross <font color="blue">profits may</font> be insufficient to allow us     to achieve and/or sustain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>As a result of our <font color="blue">collaborative</font>     <font color="blue">agreement</font>s, we are <font color="blue">dependent</font> upon the <font color="blue">development</font>, data <font color="blue">collection</font> and     marketing efforts of our licensees</td>
    </tr>
    <tr>
      <td>The amount and timing of <font color="blue">resources such</font>     <font color="blue">licensees devote</font> to these efforts are not within our control, and such     <font color="blue">licensees could</font> make material <font color="blue">decisions</font> regarding these efforts that could     <font color="blue">adversely</font> affect our <font color="blue">future <font color="blue">financial condition</font></font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, factors that <font color="blue">adversely</font> impact the <font color="blue">introduction</font> and level of     sales  of  any  drug <font color="blue">covered by</font> such licensing <font color="blue">arrangements</font>, including     <font color="blue"><font color="blue">competition</font> within</font> the <font color="blue">pharmaceutical</font> and medical device <font color="blue">industries</font>, the     timing  of  <font color="blue">regulatory</font>  or  other  approvals and <font color="blue">intellectual</font> property     <font color="blue">litigation</font>,  may  also  <font color="blue">negatively</font>  affect  sales of our <font color="blue">drug delivery</font>     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>The  failure  of  any  of our third-party licensees to develop, obtain     <font color="blue">regulatory</font>  approvals for, market, distribute and sell our products as     planned may result in us not <font color="blue">meeting revenue</font> and <font color="blue">profit targets</font>        <font color="blue">Pharmaceutical </font><font color="blue">company partners help us</font> develop, obtain <font color="blue">regulatory</font> approvals     for,  <font color="blue">manufacture</font>  and  sell  our  products</td>
    </tr>
    <tr>
      <td>If  one or more of these     <font color="blue"><font color="blue">pharmaceutical</font> company</font> partners fail to pursue the <font color="blue">development</font> or marketing     of  the  products  as  planned, our revenues and <font color="blue">profits may</font> not reach     <font color="blue">expectations</font> or may decline</td>
    </tr>
    <tr>
      <td>We may not be able to control the timing and     other aspects of the <font color="blue">development</font> of products because <font color="blue"><font color="blue">pharmaceutical</font> company</font>     partners  may  have  priorities  that  differ  from  ours</td>
    </tr>
    <tr>
      <td>Therefore,     <font color="blue">commercialization</font> of products under <font color="blue">development</font> may be <font color="blue">delayed unexpectedly</font></td>
    </tr>
    <tr>
      <td><font color="blue">Generally </font>speaking, in the near term, we do not intend to have a direct     marketing  channel  to  consumers  for  our  <font color="blue">drug delivery</font> products or     <font color="blue">technologies</font> except through current distributor <font color="blue">agreement</font>s in the United     States  for our insulin delivery device</td>
    </tr>
    <tr>
      <td>Therefore, the success of the     marketing organizations of our <font color="blue"><font color="blue">pharmaceutical</font> company</font> partners, as well as     the level of <font color="blue">priority assigned</font> to the marketing of the <font color="blue">products by</font> these     entities, which may differ from our priorities, will determine the success     of the products <font color="blue">incorporating</font> our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>in this market     could also force us to reduce the prices of our <font color="blue">technologies</font> below currently     planned  levels,  <font color="blue">which could</font> <font color="blue">adversely</font> affect our revenues and future     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>28     ______________________________________________________________________    [29]Index to <font color="blue">Financial Statements       </font>If we cannot develop and market our <font color="blue">products as rapidly</font> or cost-<font color="blue">effective</font>ly     as  our  <font color="blue">competitors</font>,  then we may never be able to achieve profitable     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>in the <font color="blue">over active bladder</font>, transdermal gel <font color="blue">drug delivery</font> and     needle-free injector market, some <font color="blue">with greater resources</font> and experience than     us, may enter the market, as there is an <font color="blue">increasing recognition</font> of a need     for <font color="blue">less invasive methods</font> of delivering drugs</td>
    </tr>
    <tr>
      <td>Additionally, there is an     <font color="blue">ever increasing list</font> of <font color="blue">competitors</font> in the oral dis<font color="blue">integrating</font> fast-melt     tablet  business</td>
    </tr>
    <tr>
      <td>Our  success  depends,  in part, upon maintaining a     <font color="blue"><font color="blue">competitive</font> position</font> in the <font color="blue">development</font> of products and <font color="blue">technologies</font> in     <font color="blue">rapidly evolving fields</font></td>
    </tr>
    <tr>
      <td>If we cannot maintain <font color="blue"><font color="blue">competitive</font> products</font> and     <font color="blue">technologies</font>, our current and potential <font color="blue"><font color="blue">pharmaceutical</font> company</font> partners may     choose to adopt the <font color="blue">drug delivery</font> <font color="blue">technologies</font> of our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Drug     </font>delivery  companies that <font color="blue">compete with</font> our <font color="blue">technologies</font> include Bioject     Medical Technologies, Inc, Bentley Pharmaceuticals, Inc, Aradigm, Cellegy     Pharmaceuticals,  Inc,  Watson Pharmaceuticals, Cardinal Health, CIMA     Laboratories, Laboratoires Besins-Iscovesco, MacroChem Corporation, NexMed,     Inc</td>
    </tr>
    <tr>
      <td>and  Novavax,  Inc, <font color="blue">along with</font> other companies</td>
    </tr>
    <tr>
      <td>We <font color="blue">also compete</font>     <font color="blue">generally</font>  with  other <font color="blue">drug delivery</font>, <font color="blue">bio<font color="blue">technology</font></font> and <font color="blue">pharmaceutical</font>     companies  engaged  in  the  <font color="blue">development</font>  of <font color="blue">alternative</font> <font color="blue">drug delivery</font>     <font color="blue">technologies</font> or <font color="blue">new drug research</font> and testing</td>
    </tr>
    <tr>
      <td>Many of these <font color="blue">competitors</font>     have  <font color="blue">substantially</font>  greater  financial, <font color="blue">technological</font>, <font color="blue">manufacturing</font>,     marketing, managerial and research and <font color="blue">development</font> resources and experience     than we do, and, therefore, represent <font color="blue">significant</font> <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>Additionally, new <font color="blue">drug delivery</font> <font color="blue">technologies</font> are <font color="blue">mostly used only with drugs</font>     for which other <font color="blue">drug delivery</font> methods are not possible, in <font color="blue">particular with</font>     bio<font color="blue">pharmaceutical</font> proteins (drugs derived from living organisms, such as     insulin and <font color="blue">human growth hormone</font>) that <font color="blue">cannot currently</font> be delivered orally     or <font color="blue">transdermally</font></td>
    </tr>
    <tr>
      <td><font color="blue">Transdermal </font>patches and gels are also used for drugs that     cannot be delivered orally or where <font color="blue">oral delivery</font> has other <font color="blue">limitations</font>     (such as high first pass drug metabolism, meaning that the <font color="blue">drug dissipates</font>     quickly  in  the  digestive  system  and, therefore, requires frequent     <font color="blue">administration</font>)</td>
    </tr>
    <tr>
      <td>Many companies, both large and small, are engaged in     research and <font color="blue">development</font> efforts on <font color="blue">less invasive methods</font> of delivering     drugs that cannot be <font color="blue">taken orally</font></td>
    </tr>
    <tr>
      <td>The successful <font color="blue">development</font> and commercial     <font color="blue">introduction</font> of such a non-injection technique could have a material adverse     effect on our business, <font color="blue">financial condition</font>, results of <font color="blue">operations</font> and     <font color="blue">general prospects</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may succeed in developing competing <font color="blue">technologies</font> or obtaining     <font color="blue">governmental approval</font> for products before we do</td>
    </tr>
    <tr>
      <td>Competitors’ products may     gain market <font color="blue">acceptance</font> more <font color="blue">rapidly than</font> our products, or may be priced more     <font color="blue">favorably than</font> our products</td>
    </tr>
    <tr>
      <td><font color="blue">Developments </font>by <font color="blue">competitors</font> may render our     products, or potential products, non<font color="blue">competitive</font> or obsolete</td>
    </tr>
    <tr>
      <td>Although we have applied for, and have received, <font color="blue">several patents</font>, we may be     unable to protect our <font color="blue">intellectual</font> property, which would <font color="blue">negatively</font> affect     our ability to compete        Our <font color="blue">success depends</font>, in part, on our ability to obtain and <font color="blue">enforce patents</font>     for our products, processes and <font color="blue">technologies</font> and to preserve our trade     secrets  and  other  <font color="blue">proprietary</font>  information</td>
    </tr>
    <tr>
      <td>If we cannot do so, our     <font color="blue">competitors</font> may exploit our <font color="blue">innovations</font> and <font color="blue">deprive us</font> of the ability to     realize revenues and <font color="blue">profits from</font> our <font color="blue">development</font>s</td>
    </tr>
    <tr>
      <td>Currently,  we  have  been  granted  32  patents and an <font color="blue">additional</font> 111     <font color="blue">applications</font>  pending  in  the  US  and  other countries</td>
    </tr>
    <tr>
      <td>Any patent     <font color="blue">applications</font> we may have made or may make relating to <font color="blue">inventions</font> for our     actual or potential products, processes and <font color="blue">technologies</font> may not result in     patents being issued or may result in patents that provide insufficient or     <font color="blue">incomplete coverage</font> for our <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">current patents may</font> not be valid     or enforceable and may not protect us against <font color="blue">competitors</font> that challenge our     patents, obtain their own patents that may have an adverse effect on our     ability  to  conduct business, or are able to <font color="blue">otherwise circumvent</font> our     patents</td>
    </tr>
    <tr>
      <td>Further, we may not have the <font color="blue">necessary financial resources</font> to     enforce or defend our patents or patent <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>To protect our <font color="blue">trade secrets</font> and <font color="blue">proprietary</font> <font color="blue">technologies</font> and processes, we     rely, in part, on confidentiality <font color="blue">agreement</font>s with employees, consultants and     advisors</td>
    </tr>
    <tr>
      <td>These <font color="blue">agreement</font>s may not <font color="blue">provide adequate protection</font> for our trade     secrets and other <font color="blue">proprietary</font> information in the event of any <font color="blue">unauthorized</font>     use or <font color="blue">disclosure</font>, or if <font color="blue">others lawfully</font> and in<font color="blue">dependent</font>ly develop the same     or similar information</td>
    </tr>
    <tr>
      <td>Others  may  bring  <font color="blue">infringement</font>  claims  against  us,  <font color="blue">which could</font> be     time-consuming and expensive to defend        Third  <font color="blue">parties may</font> claim that the <font color="blue">manufacture</font>, use or sale of our drug     delivery <font color="blue">technologies</font> infringe their <font color="blue">patent rights</font></td>
    </tr>
    <tr>
      <td>If such claims are     asserted, we may have to seek licenses, defend <font color="blue">infringement</font> actions or     challenge  the validity of those patents in court</td>
    </tr>
    <tr>
      <td>If we cannot obtain     required licenses, are <font color="blue">found liable</font> for <font color="blue">infringement</font> or are not                                           29     ______________________________________________________________________    [30]Index to <font color="blue">Financial Statements       </font>able  to  have  these  patents  declared invalid, we may be liable for     <font color="blue">significant</font> monetary damages, encounter <font color="blue"><font color="blue">significant</font> delays</font> in bringing     products to market or be <font color="blue">precluded from participating</font> in the <font color="blue">manufacture</font>,     use or sale of products or methods of <font color="blue">drug delivery</font> <font color="blue">covered by</font> the patents     of others</td>
    </tr>
    <tr>
      <td>We may not have identified, or be able to identify in the future,     <font color="blue">United States </font>or foreign patents that pose a risk of potential <font color="blue">infringement</font>     claims</td>
    </tr>
    <tr>
      <td>If the <font color="blue">pharmaceutical</font> companies to which we license our <font color="blue">technologies</font> lose     their patent protection or face patent <font color="blue">infringement</font> claims for their drugs,     we may not realize our revenue or profit plan        The drugs to which our <font color="blue">drug delivery</font> <font color="blue">technologies</font> are applied are <font color="blue">generally</font>     the property of the <font color="blue">pharmaceutical</font> companies</td>
    </tr>
    <tr>
      <td>Those drugs may be the subject     of patents or patent <font color="blue">applications</font> and other forms of protection owned by the     <font color="blue">pharmaceutical</font> companies or <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>If those patents or other forms     of protection expire, become in<font color="blue">effective</font> or are subject to the control of     third  parties, sales of the drugs by the collaborating <font color="blue">pharmaceutical</font>     <font color="blue">company may</font> be restricted or may cease</td>
    </tr>
    <tr>
      <td>Our expected revenues, in that     event, may not <font color="blue">materialize</font> or may decline</td>
    </tr>
    <tr>
      <td>Our business may suffer if we <font color="blue">lose certain <font color="blue">key officers</font></font> or employees or if     we are not able to add <font color="blue">additional</font> <font color="blue">key officers</font> or <font color="blue">employees necessary</font> to     reach our goals        The success of our business is materially <font color="blue">dependent</font> upon the continued     services of certain of our <font color="blue">key officers</font> and employees</td>
    </tr>
    <tr>
      <td>The loss of such key     <font color="blue">personnel could</font> have a material adverse effect on our business, operating     results or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that we will be     successful in retaining <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>We consider our <font color="blue">employee relations</font> to     be good; however, <font color="blue">competition</font> for personnel is intense and we cannot assume     that we <font color="blue">will continue</font> to be able to attract and retain personnel of high     caliber</td>
    </tr>
    <tr>
      <td>We are involved in <font color="blue">international markets</font>, and this <font color="blue">subjects us</font> to <font color="blue">additional</font>     business risks        We have offices and a <font color="blue">research facility</font> in Basel, Switzerland, and we also     license and distribute our products in the European Community and the United     States</td>
    </tr>
    <tr>
      <td>These <font color="blue">geographic localities provide economically</font> and <font color="blue">politically</font>     <font color="blue">stable environments</font> in which to operate</td>
    </tr>
    <tr>
      <td>However, in the future, we intend     to <font color="blue">introduce products through partnerships</font> in other countries</td>
    </tr>
    <tr>
      <td>As we expand     our <font color="blue">geographic market</font>, we will face <font color="blue">additional</font> ongoing complexity to our     business and <font color="blue">may encounter</font> the following <font color="blue">additional</font> risks:           •   <font color="blue">increased complexity</font> and costs of managing international <font color="blue">operations</font>;           •   <font color="blue">protectionist laws</font> and business practices that <font color="blue">favor local companies</font>;           •   <font color="blue">dependence on local vendors</font>;           •   multiple, conflicting and changing <font color="blue">governmental laws</font> and <font color="blue">regulations</font>;           •   <font color="blue"><font color="blue">difficult</font>ies</font> in enforcing our <font color="blue">legal rights</font>;           •   reduced or limited <font color="blue">protections</font> of <font color="blue">intellectual</font> property rights; and           •   political and <font color="blue">economic <font color="blue">instability</font></font></td>
    </tr>
    <tr>
      <td>A  <font color="blue">significant</font> portion of our international revenues is <font color="blue">denominated</font> in     <font color="blue">foreign currencies</font></td>
    </tr>
    <tr>
      <td>An increase in the value of the US <font color="blue">dollar relative</font> to     these  <font color="blue">currencies may</font> make our products more expensive and, thus, less     <font color="blue">competitive</font> in <font color="blue">foreign markets</font></td>
    </tr>
    <tr>
      <td>If we make any <font color="blue"><font color="blue">acquisition</font>s</font>, we will incur a variety of costs and might     never <font color="blue">successfully</font> integrate the acquired product or business into ours</td>
    </tr>
    <tr>
      <td>We <font color="blue">might attempt</font> to acquire products or businesses that we believe are a     <font color="blue">strategic complement</font> to our business model</td>
    </tr>
    <tr>
      <td>We <font color="blue">might encounter</font> operating     <font color="blue"><font color="blue">difficult</font>ies</font> and <font color="blue">expenditures</font> relating to <font color="blue">integrating</font> an acquired product or     business</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">acquisition</font>s</font> might require <font color="blue">significant</font> management attention     that <font color="blue">would otherwise</font> be available for ongoing <font color="blue">development</font> of our business</td>
    </tr>
    <tr>
      <td>In  addition,  we  <font color="blue">might never</font> realize the anticipated benefits of any     <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">might also</font> make <font color="blue">dilutive issuances</font> of <font color="blue">equity securities</font>,     incur debt or experience a decrease in <font color="blue">cash available</font> for our <font color="blue">operations</font>, or     incur  contingent liabilities and/or amortization expenses relating to     goodwill  and  other  intangible  assets,  in  <font color="blue">connection</font>  <font color="blue">with future</font>     <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>30     ______________________________________________________________________    [31]Index to <font color="blue">Financial Statements       </font>If we do not have <font color="blue">adequate insurance</font> for <font color="blue">product <font color="blue">liability</font></font> claims, then we     may be subject to <font color="blue">significant</font> expenses relating to these claims</td>
    </tr>
    <tr>
      <td>The  Company’s  business entails the risk of <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td><font color="blue">Although the Company </font>has not experienced any material <font color="blue">product <font color="blue">liability</font></font>     claims to date, any such claims could have a material <font color="blue">adverse impact on</font> its     business</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>maintains <font color="blue">product <font color="blue">liability</font></font> insurance with coverage of     dlra5 million per occurrence and an <font color="blue">annual aggregate maximum</font> of dlra5 million</td>
    </tr>
    <tr>
      <td>The     Company evaluates its insurance <font color="blue">requirements</font> on an <font color="blue">ongoing basis</font></td>
    </tr>
    <tr>
      <td>Geopolitical, economic and <font color="blue">military conditions</font>, including <font color="blue">terrorist attacks</font>     and other acts of war, may materially and <font color="blue">adversely</font> affect the markets on     which  our  common  <font color="blue">stock trades</font>, the markets in which we operate, our     <font color="blue">operations</font> and our <font color="blue">profitability</font>        <font color="blue">Terrorist </font>attacks, such as those that occurred on <font color="blue">September </font>11, 2001, and     other acts of war, and any response to them, may lead to <font color="blue">armed <font color="blue">hostilities</font></font>     and such <font color="blue">development</font>s would likely cause <font color="blue">instability</font> in <font color="blue">financial markets</font></td>
    </tr>
    <tr>
      <td>Armed  <font color="blue">hostilities</font>  and  <font color="blue">terrorism may directly impact</font> our <font color="blue">facilities</font>,     personnel  and  <font color="blue">operations</font>, which are located <font color="blue">in the <font color="blue">United States </font></font>and     Switzerland, as well as those of our clients</td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">severe terrorist</font>     attacks or acts of war may result in <font color="blue">temporary halts</font> of <font color="blue">commercial activity</font>     in the <font color="blue">affected regions</font>, and may result in <font color="blue">reduced demand</font> for our products</td>
    </tr>
    <tr>
      <td>These <font color="blue">development</font>s could have a material adverse effect on our business and     the <font color="blue">trading price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related </font>to <font color="blue">Regulatory </font>Matters        We or our licensees may incur <font color="blue">significant</font> costs seeking approval for our     products, <font color="blue">which could</font> delay the <font color="blue">realization</font> of revenue and, ultimately,     decrease our <font color="blue">revenues from</font> such products        The  design,  <font color="blue">development</font>,  testing,  <font color="blue">manufacturing</font>  and  marketing of     <font color="blue">pharmaceutical</font> compounds, medical nutrition and <font color="blue">diagnostic products</font> and     <font color="blue">medical devices</font> are subject to <font color="blue">regulation by governmental <font color="blue">authorities</font></font>,     including the FDA and comparable <font color="blue">regulatory</font> <font color="blue">authorities</font> in other countries</td>
    </tr>
    <tr>
      <td>The  approval  process  is <font color="blue">generally</font> lengthy, expensive and subject to     <font color="blue">unanticipated delays</font></td>
    </tr>
    <tr>
      <td>Currently, we, <font color="blue">along with</font> our partners, are actively     pursuing  marketing  approval for a number of <font color="blue">products from</font> <font color="blue">regulatory</font>     <font color="blue">authorities</font> in other countries and anticipate seeking <font color="blue">regulatory</font> approval     from the FDA for products developed pursuant to our <font color="blue">agreement</font> with BioSante</td>
    </tr>
    <tr>
      <td>Our revenue and <font color="blue">profit will depend</font>, in part, on the     successful <font color="blue">introduction</font> and marketing of some or all of such <font color="blue">products by</font> our     partners  or  us</td>
    </tr>
    <tr>
      <td>There can be <font color="blue">no assurance as</font> to when or <font color="blue">whether such</font>     approvals from <font color="blue">regulatory</font> <font color="blue">authorities</font> will be received</td>
    </tr>
    <tr>
      <td><font color="blue">Applicants for FDA </font><font color="blue">approval often must submit</font> extensive <font color="blue">clinical data</font> and     supporting information to the <font color="blue">FDA Varying </font><font color="blue">interpretations</font> of the data     obtained  from pre-clinical and clinical testing could delay, limit or     prevent <font color="blue">regulatory</font> approval of a <font color="blue">drug product</font></td>
    </tr>
    <tr>
      <td><font color="blue">Changes in FDA </font>approval     <font color="blue">policy during</font> the <font color="blue">development</font> period, or changes in <font color="blue">regulatory</font> review for     <font color="blue">each submitted new drug application also may</font> cause delays or rejection of an     approval</td>
    </tr>
    <tr>
      <td>Even if the FDA approves a product, the <font color="blue">approval may limit</font> the     uses or “<font color="blue">indications</font>” for which a <font color="blue">product may</font> be marketed, or may require     <font color="blue">further studies</font></td>
    </tr>
    <tr>
      <td>The FDA also can <font color="blue">withdraw product clearances</font> and approvals     for failure to <font color="blue">comply with</font> <font color="blue">regulatory</font> <font color="blue">requirements</font> or if <font color="blue">unforeseen problems</font>     <font color="blue">follow initial marketing</font></td>
    </tr>
    <tr>
      <td>In other <font color="blue">jurisdictions</font>, we, and the <font color="blue">pharmaceutical</font> companies with whom we     are developing <font color="blue">technologies</font>, must obtain required <font color="blue">regulatory</font> approvals from     <font color="blue">regulatory</font> agencies and <font color="blue">comply with</font> extensive <font color="blue">regulations</font> regarding safety     and quality</td>
    </tr>
    <tr>
      <td>If approvals to market the products are delayed, if we fail to     receive these approvals, or if we <font color="blue">lose previously</font> received approvals, our     <font color="blue">revenues may</font> not <font color="blue">materialize</font> or may decline</td>
    </tr>
    <tr>
      <td>We may not be able to obtain     all necessary <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>We may be required to incur <font color="blue">significant</font>     costs in obtaining or maintaining <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>31     ______________________________________________________________________    [32]Index to <font color="blue">Financial Statements       </font>Our  business  could  be  harmed  if we fail to <font color="blue">comply with</font> <font color="blue">regulatory</font>     <font color="blue">requirements</font> and, as a result, are subject to sanctions        If we, or <font color="blue">pharmaceutical</font> companies with whom we are developing <font color="blue">technologies</font>,     fail to <font color="blue">comply with</font> applicable <font color="blue">regulatory</font> <font color="blue">requirements</font>, the <font color="blue">pharmaceutical</font>     companies, and we, may be subject to sanctions, including the following:           •   <font color="blue">warning letters</font>;           •   fines;           •   <font color="blue">product seizures</font> or recalls;           •   <font color="blue">injunctions</font>;           •   refusals to <font color="blue">permit products</font> to be <font color="blue">imported into</font> or <font color="blue">exported out</font> of the     applicable <font color="blue">regulatory</font> jurisdiction;           •   total or <font color="blue">partial suspension</font> of production;           •   <font color="blue">withdrawals</font> of previously approved marketing <font color="blue">applications</font>; or           •   <font color="blue">criminal prosecutions</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">revenues may</font> be limited if the marketing claims asserted about our     products are not approved        Once a <font color="blue">drug product</font> is <font color="blue">approved by</font> the FDA, the <font color="blue">Division of Drug Marketing</font>,     Advertising and Communication, the FDA’s <font color="blue">marketing surveillance</font> department     within the Center for Drugs, <font color="blue">must approve marketing</font> claims asserted by our     <font color="blue"><font color="blue">pharmaceutical</font> company</font> partners</td>
    </tr>
    <tr>
      <td>If we or a <font color="blue"><font color="blue">pharmaceutical</font> company</font> partner     fails to obtain from the <font color="blue">Division of Drug <font color="blue">Marketing </font></font>acceptable marketing     claims for a product <font color="blue">incorporating</font> our drug <font color="blue">technologies</font>, our <font color="blue">revenues from</font>     that <font color="blue">product may</font> be limited</td>
    </tr>
    <tr>
      <td><font color="blue">Marketing </font>claims are the basis for a product’s     labeling, advertising and promotion</td>
    </tr>
    <tr>
      <td>The claims the <font color="blue"><font color="blue">pharmaceutical</font> company</font>     partners are asserting about our <font color="blue">drug delivery</font> <font color="blue">technologies</font>, or the drug     product itself, may not be <font color="blue">approved by</font> the <font color="blue">Division of Drug Marketing</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims related to <font color="blue">participation</font> in <font color="blue">clinical trials</font> or the     use or misuse of our <font color="blue">products could prove</font> to be costly to defend and could     harm our business reputation        The testing, <font color="blue">manufacturing</font> and marketing of <font color="blue">products utilizing</font> our drug     delivery <font color="blue">technologies</font> may expose us to potential <font color="blue">product <font color="blue">liability</font></font> and other     claims resulting from their use in practice or in clinical <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>If     any  such claims <font color="blue">against us</font> are successful, we may be required to make     <font color="blue">significant</font>  <font color="blue">compensation</font>  payments</td>
    </tr>
    <tr>
      <td>Any <font color="blue">indemnification</font> that we have     obtained,  or  may  obtain,  from  contract  <font color="blue">research organizations</font> or     <font color="blue">pharmaceutical</font> companies conducting human <font color="blue">clinical trials</font> on our <font color="blue">behalf may</font>     not protect us from <font color="blue">product <font color="blue">liability</font></font> claims or from the costs of related     <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Similarly, any <font color="blue">indemnification</font> we have obtained, or may obtain,     from <font color="blue">pharmaceutical</font> companies with whom we are developing <font color="blue">drug delivery</font>     <font color="blue">technologies</font> may not protect us from <font color="blue">product <font color="blue">liability</font></font> claims from the     consumers of those products or from the costs of related <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>If we     are subject to a <font color="blue">product <font color="blue">liability</font></font> claim, our <font color="blue">product <font color="blue">liability</font></font> insurance     may not <font color="blue">reimburse us</font>, or may not be sufficient to <font color="blue">reimburse us</font>, for any     expenses  or  losses that may have <font color="blue">been suffered</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">successful product</font>     <font color="blue">liability</font>  claim <font color="blue">against us</font>, if not <font color="blue">covered by</font>, or if in excess of our     <font color="blue">product <font color="blue">liability</font></font> insurance, may require us to make <font color="blue">significant</font> <font color="blue">compensation</font>     payments,  which  would  be  <font color="blue">reflected as expenses on</font> our statement of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Adverse  </font>claim  experience  for  our products or licensed     <font color="blue">technologies</font> or medical device, <font color="blue">pharmaceutical</font> or <font color="blue">insurance industry trends</font>     may make it <font color="blue">difficult</font> for us to obtain <font color="blue">product <font color="blue">liability</font></font> insurance or we may     be forced to pay very <font color="blue">high premiums</font>, and there can be no assurance that     insurance coverage <font color="blue">will continue</font> to be <font color="blue">available on commercially reasonable</font>     terms or at all</td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related </font>to our Common Stock        Together, certain of our <font color="blue">stockholders</font> own or have the right to acquire a     <font color="blue">significant</font> portion of our stock and could ultimately control <font color="blue">decisions</font>     regarding our company        As a result of our reverse business <font color="blue">combination</font> with Permatec in January     2001 and subsequent <font color="blue">additional</font> debt and <font color="blue">equity financings</font>, Permatec Holding     AG and its <font color="blue">controlling</font> <font color="blue">shareholder</font>, Dr</td>
    </tr>
    <tr>
      <td>Jacques Gonella, own a substantial     portion (as of March 3, 2006, <font color="blue">approximately</font> 18prca) of our <font color="blue">outstanding shares</font>     of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Gonella, who is <font color="blue">the Chairman </font>of our Board of Directors,     also owns warrants to purchase an aggregate of 4cmam198cmam976 shares of common     stock and options to purchase 104cmam500 shares of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Additionally,     <font color="blue">five investors</font> (Crestview Capital Master Fund, <font color="blue">North Sound </font>Funds, Perceptive     Life Sciences Fund, SCO Capital Group and SDS Funds) own warrants that are,     as of March 3, 2006, exercisable into an aggregate of 6cmam162cmam904 shares of     our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Some of these investors plus <font color="blue">Atlas Equity </font><font color="blue">also directly</font>     own an aggregate of <font color="blue">approximately</font> 5cmam419cmam884 shares of our                                           32     ______________________________________________________________________    [33]Index to <font color="blue">Financial Statements       </font><font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Gonella and all of the above <font color="blue">investors exercised</font> all of     the warrants and options owned by them, Dr</td>
    </tr>
    <tr>
      <td>Gonella would own <font color="blue">approximately</font>     17prca, and the <font color="blue">six investors as</font> a group would own <font color="blue">approximately</font> 13prca, of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>the  parties  described  above  either currently own or could     <font color="blue">potentially</font> own a large portion of our stock, they may be able to <font color="blue">generally</font>     determine or they will be able to <font color="blue"><font color="blue">significant</font>ly</font> influence the outcome of     corporate actions requiring stockholder approval</td>
    </tr>
    <tr>
      <td>As a result, these parties     may be in a position to control matters affecting our company, including     <font color="blue">decisions</font> as to our <font color="blue">corporate direction</font> and policies; future issuances of     <font color="blue">certain securities</font>; our incurrence of debt; amendments to our <font color="blue">certificate</font> of     <font color="blue">incorporation</font> and bylaws; payment of <font color="blue">dividends on</font> our <font color="blue">common stock</font>; and     <font color="blue"><font color="blue">acquisition</font>s</font>,  sales  of  our assets, mergers or similar <font color="blue">transactions</font>,     including <font color="blue">transactions</font> involving a change of control</td>
    </tr>
    <tr>
      <td>In addition, if the     demand  for our <font color="blue">common stock</font> is reduced because of these <font color="blue">stockholders</font>’     control of the Company, the price of our <font color="blue">common stock</font> could be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>Certain of our <font color="blue">stockholders</font> own large blocks of our <font color="blue">common stock</font> and own     securities  or  exercisable  into  shares of our <font color="blue">common stock</font>, and any     exercises, or sales by these <font color="blue">stockholders</font> could <font color="blue">substantially</font> lower the     <font color="blue">market price</font> of our <font color="blue">common stock</font>        Several of our <font color="blue">shareholder</font>s, including Dr</td>
    </tr>
    <tr>
      <td>Gonella, <font color="blue">whose sales</font> are subject     to volume <font color="blue">limitations</font>, Atlas Equity, Crestview Capital Master Fund, SCO     Capital Group, the SDS funds, the <font color="blue">North Sound </font>funds and Perceptive Life     Sciences Master Fund, own large blocks of our <font color="blue">common stock</font> or could own     <font color="blue">sizeable blocks</font> of our <font color="blue">common stock</font> upon exercise of warrants</td>
    </tr>
    <tr>
      <td>With the     exception of a portion of the <font color="blue">stock controlled by</font> Dr</td>
    </tr>
    <tr>
      <td>Gonella, the shares of     our <font color="blue">common stock</font> owned by these <font color="blue">stockholders</font> (or issuable to them upon     exercise of warrants or options) are registered or <font color="blue">registration</font> will be     applied for in the near future</td>
    </tr>
    <tr>
      <td>Future sales of large blocks of our common     stock by any of the above investors could <font color="blue">substantially</font> <font color="blue">adversely</font> affect our     stock price</td>
    </tr>
    <tr>
      <td>Future <font color="blue">conversions</font> or <font color="blue">exercises by holders</font> of warrants or <font color="blue">options could</font>     <font color="blue">substantially</font> dilute our <font color="blue">common stock</font>        <font color="blue">As of March </font>3, 2006, we have <font color="blue">warrants outstanding</font> that are exercisable, at     prices ranging from dlra0dtta55 per share to dlra7dtta03 per share, for an aggregate of     <font color="blue">approximately</font> 22cmam500cmam000 shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Purchasers  </font>of <font color="blue">common stock</font> could therefore experience     substantial dilution of their <font color="blue">investment</font> upon exercise of the above warrants     or options</td>
    </tr>
    <tr>
      <td>The warrants and the options are not registered and may be sold     only if <font color="blue">registered under</font> the <font color="blue">Securities Act </font>of 1933, as amended, or sold in     <font color="blue"><font color="blue">accordance</font> with</font> an applicable exemption from <font color="blue">registration</font>, such as Rule 144</td>
    </tr>
    <tr>
      <td>The shares of <font color="blue">common stock</font> issuable upon exercise of the warrants or options     held by these investors are <font color="blue">currently registered</font> or <font color="blue">registration</font> will be     applied for in the near future</td>
    </tr>
    <tr>
      <td>Sales of our <font color="blue">common stock</font> by our officers and <font color="blue">directors</font> may lower the market     price of our <font color="blue">common stock</font>        As  of March 3, 2006, our officers and <font color="blue">directors</font> beneficially owned an     aggregate of <font color="blue">approximately</font> 15cmam200cmam000 shares (or <font color="blue">approximately</font> 26prca) of our     <font color="blue">common stock</font>, including stock options exercisable within 60 days</td>
    </tr>
    <tr>
      <td>If our     officers and <font color="blue">directors</font>, or other <font color="blue">shareholder</font>s, sell a substantial amount of     our <font color="blue">common stock</font>, it could cause the <font color="blue">market price</font> of our <font color="blue">common stock</font> to     decrease and <font color="blue">could hamper</font> our ability to <font color="blue">raise capital through</font> the sale of     our <font color="blue">equity securities</font></td>
    </tr>
    <tr>
      <td>We do not expect to pay dividends in the <font color="blue">foreseeable future</font>        We intend to retain any earnings in the <font color="blue">foreseeable future</font> for our continued     growth and, thus, do not expect to declare or pay any <font color="blue">cash dividends</font> in the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>33     ______________________________________________________________________    [34]Index to <font color="blue">Financial Statements       </font>Anti-takeover effects of certain <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaw     provisions could discourage, delay or prevent a change in control</td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaws could discourage, delay or     <font color="blue">prevent persons from</font> acquiring or attempting to acquire us</td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font>s     of <font color="blue">incorporation</font> authorizes our board of <font color="blue">directors</font>, without action of our     <font color="blue">stockholders</font>, to designate and <font color="blue">issue preferred stock</font> in one or more series,     with such rights, preferences and <font color="blue">privileges as</font> the board of <font color="blue">directors</font> shall     determine</td>
    </tr>
    <tr>
      <td>In  addition,  our bylaws grant our board of <font color="blue">directors</font> the     authority to adopt, amend or repeal all or any of our bylaws, subject to the     power of the <font color="blue">stockholders</font> to change or repeal the bylaws</td>
    </tr>
    <tr>
      <td>In addition, our     <font color="blue">bylaws limit</font> who <font color="blue">may call meetings</font> of our <font color="blue">stockholders</font></td>
    </tr>
  </tbody>
</table>